JP2022552156A5 - - Google Patents

Info

Publication number
JP2022552156A5
JP2022552156A5 JP2022520588A JP2022520588A JP2022552156A5 JP 2022552156 A5 JP2022552156 A5 JP 2022552156A5 JP 2022520588 A JP2022520588 A JP 2022520588A JP 2022520588 A JP2022520588 A JP 2022520588A JP 2022552156 A5 JP2022552156 A5 JP 2022552156A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
salt according
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022552156A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/059274 external-priority patent/WO2021064677A1/en
Publication of JP2022552156A publication Critical patent/JP2022552156A/ja
Publication of JP2022552156A5 publication Critical patent/JP2022552156A5/ja
Pending legal-status Critical Current

Links

JP2022520588A 2019-10-04 2020-10-02 ヒト免疫不全ウイルスの複製阻害剤 Pending JP2022552156A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910684P 2019-10-04 2019-10-04
US62/910,684 2019-10-04
PCT/IB2020/059274 WO2021064677A1 (en) 2019-10-04 2020-10-02 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2022552156A JP2022552156A (ja) 2022-12-15
JP2022552156A5 true JP2022552156A5 (cg-RX-API-DMAC10.html) 2023-10-11

Family

ID=73014547

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520588A Pending JP2022552156A (ja) 2019-10-04 2020-10-02 ヒト免疫不全ウイルスの複製阻害剤

Country Status (6)

Country Link
US (1) US20230013823A1 (cg-RX-API-DMAC10.html)
EP (1) EP4038061A1 (cg-RX-API-DMAC10.html)
JP (1) JP2022552156A (cg-RX-API-DMAC10.html)
AR (1) AR120150A1 (cg-RX-API-DMAC10.html)
TW (1) TW202128648A (cg-RX-API-DMAC10.html)
WO (1) WO2021064677A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
JP7361766B2 (ja) * 2018-09-14 2023-10-16 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
WO2020058844A1 (en) * 2018-09-20 2020-03-26 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020084491A1 (en) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MA53973A (fr) * 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
PT3870575T (pt) * 2018-10-25 2023-05-12 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
EP4038068A1 (en) * 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
ES2974657T3 (es) * 2019-10-01 2024-07-01 Viiv Healthcare Uk No 5 Ltd Derivados de n-substituido-6-oxo-1,6-dihidropirimidina-2-ilo como inhibidores de la replicación del virus de inmunodeficiencia humana
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
US12703699B2 (en) * 2020-03-06 2026-08-11 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
WO2021176366A1 (en) * 2020-03-06 2021-09-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP4135702B1 (en) * 2020-04-15 2026-06-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
AU2022362855B2 (en) * 2021-10-13 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
DK2997019T3 (en) SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
JP2021169499A5 (cg-RX-API-DMAC10.html)
JP2019069941A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
KR102519536B1 (ko) 트리시클릭 회전장애이성질체 화합물
TW202321201A (zh) 化合物及其用途
JP2022551254A5 (cg-RX-API-DMAC10.html)
JP6469214B2 (ja) N−アシル−(3−置換)−(8−置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンの新規キラル合成
JP2013533291A5 (cg-RX-API-DMAC10.html)
JP7797486B2 (ja) 新規なrho関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
CN117715906A (zh) 胰高血糖素样肽-1受体调节剂及其用途
JP2023509001A (ja) Khk阻害効果を有する化合物
CN105452259A (zh) 三环苯并氧杂硼化合物、其制备方法与应用
CN114105950A (zh) 吡唑类化合物及其应用
WO2015172732A1 (zh) 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
TW202233614A (zh) 作為激酶抑制劑之三唑并吡啶化合物
WO2021064677A1 (en) Inhibitors of human immunodeficiency virus replication
KR20250038236A (ko) 코로나바이러스 감염 치료용 화합물
CN118791481A (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
WO2017202357A1 (zh) 一种三氟甲基取代的吡喃衍生物的制备方法
CN110698380B (zh) 一种内酰胺衍生物及其制备方法与应用
KR20230128511A (ko) 신규한 오토택신 억제제
WO2016196932A1 (en) Process for preparing substituted tetracyclic heterocycle compounds
CN116134025B (zh) 酰胺膦氧类衍生物及其制备方法和用途
JPH07242670A (ja) ピロロ[3,2−e]ピラゾロ[1,5−a]ピリミジン誘導体及びこれを含有する循環器系疾患治療剤
CN110759901A (zh) 四氢异喹啉类衍生物及其制备方法和用途